Swaminathan P. Iyer

Has grant

Professor of Medicine

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Swaminathan P. Iyer is a Professor of Medicine at The University of Texas MD Anderson Cancer Center in the United States. His research focuses on organ dysfunction in lymphoma, treatment outcomes in peripheral T-cell lymphoma, and the management of mucositis in PTCL/CTCL. He has contributed to studies concerning CAR T-cell therapy, the role of radiation in lymphoma management, and the impact of demographics on clinical trial participation.

Recent Grants

Grant: Close

Cancer Therapy & Research Center at UTHSCSA

Open Date: 1991-09-01

Close Date: 2019-07-31

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (15)

Matthew Mei

Associate Professor

City of Hope

UNITED STATES

Swaminathan P. Iyer

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Pralatrexate injection combined with oral leucovorin for mucositis management in PTCL/CTCL treatment: a multicenter phase 2 trial

The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma

Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma

Low CD25 in ALK+ Anaplastic Large Cell Lymphoma Is Associated with Older Age, Thrombocytopenia, and Increased Expression of Surface CD3 and CD8

Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes

Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL

Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.

Early-Stage Extranodal NK/T-Cell Lymphoma, Nasal Type: A Role for Elective Nodal Irradiation?

Beyond surgery: the proper role and delivery of radiation therapy in the local-regional management of BIA-ALCL.

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.

Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant

Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma

From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature

Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.

Complete Response to tenalisib and romidepsin with long-term maintenance using tenalisib monotherapy in a patient with relapsed and refractory sézary syndrome.

Newer insights on how to TEC down T-ALL

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response

Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy

<i>DUSP22</i> rearrangement is associated with distinctive immunophenotype but not outcome in patients with systemic ALK-negative anaplastic large cell lymphoma.

Evolving Landscape of Antibody Drug Conjugates in Lymphoma.

Collaborators (15)

Matthew Mei

sairah ahmed

Michi Shinohara

Andres E. Quesada

Guy Handley

Qaiser Bashir

John Radford

Fareed Khawaja

Francine Foss

L. Jeffrey Medeiros

Nahum Puebla

C. Cameron Yin

Joseph Sassine

Elias J. Jabbour

Jeremy Ramdial

Make your next move.